News and Events - Affimed

News

All categories

Earnings

Press Release

All years

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

Affimed to Speak at Symposium on Emerging Approaches in Cancer Immunotherapy

February 22, 2016

Affimed to Present at the Leerink Partners 5th Annual Global Healthcare Conference

February 4, 2016

Affimed Enters into Collaboration with Merck to Evaluate AFM13 in Combination with KEYTRUDA^® (pembrolizumab) for Patients with Hodgkin Lymphoma

January 25, 2016

Affimed Appoints Dr. Joerg Windisch as Chief Operating Officer and Adds Dr. Bernhard Ehmer to Supervisory Board

January 21, 2016

Affimed to Host Hodgkin’s Lymphoma Day with Key Opinion Leaders on January 26th in New York City

January 20, 2016

Affimed to Present at Noble Financial Capital Markets’ 12th Annual Investor Conference

January 12, 2016

Affimed Added to NASDAQ Biotech Index^®

December 14, 2015

Affimed Presents Additional Data on Combination of AFM13 with Checkpoint Inhibitors at ASH

December 6, 2015

Affimed Presents Data Comparing T-cell- and NK-cell- engaging TandAbs AFM11 and AFM12 at ASH

December 6, 2015

Affimed Announces Appointment of Andrew Curtis to Lead Corporate Strategy and Business Development, Expansion of US Presence

December 2, 2015

Events

All

Scientific

Investors

09Dec

ASH Annual Meeting

December 9 - 12, 2023 (San Diego, USA)

Webcasts More events